Post Approval Study Evaluating the Long Term Safety and Effectiveness of the Endurant Stent Graft System (ENGAGE PAS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Aortic Aneurysm, Abdominal
- Sponsor
- Medtronic Cardiovascular
- Enrollment
- 178
- Locations
- 24
- Primary Endpoint
- Freedom From Aneurysm-related Mortality Rate (ARM) at 5 Years (1826 Days)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of the study is to demonstrate the long term safety and effectiveness of the Endurant Stent Graft System for the endovascular treatment of infrarenal abdominal aortic aneurysms in a post-approval environment, through the endpoints established in this protocol.
The clinical objective of the study is to evaluate the long term safety and effectiveness of the Endurant Stent Graft System assessed at 5 years through freedom from Aneurysm-Related Mortality (ARM).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥18 years
- •Indication for elective surgical repair of abdominal aortic aneurysm (AAA) with an endovascular stent graft in accordance with the applicable guidelines on endovascular interventions and the Instructions for Use of the Endurant Stent Graft System
- •Signed consent form. The subject or legal representative has been informed of the nature of the trial and has consented to participate and authorized the collection and release of his medical information
- •Intention to electively implant the Endurant Stent Graft System
- •Ability and willingness to comply with the Clinical Investigational Plan (CIP).
Exclusion Criteria
- •High probability of non-adherence to physician's follow-up requirements
- •Current participation in a concurrent trial which may confound study results
- •Female of childbearing potential in whom pregnancy cannot be excluded or who is lactating.
Outcomes
Primary Outcomes
Freedom From Aneurysm-related Mortality Rate (ARM) at 5 Years (1826 Days)
Time Frame: 5 years
Aneurysm-Related Mortality (ARM) is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should be aneurysm related. \> All deaths will be adjudicated by a Clinical Events Committee (CEC) to determine device, procedure and/or AAA relatedness.